<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1252" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1252/" /><meta name="ncbi_pagename" content="Hereditary Leiomyomatosis and Renal Cell Cancer - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Hereditary Leiomyomatosis and Renal Cell Cancer - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Hereditary Leiomyomatosis and Renal Cell Cancer" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2015/08/06" /><meta name="citation_author" content="Manop Pithukpakorn" /><meta name="citation_author" content="Jorge R Toro" /><meta name="citation_pmid" content="20301430" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1252/" /><meta name="citation_keywords" content="HLRCC" /><meta name="citation_keywords" content="HLRCC" /><meta name="citation_keywords" content="Hereditary Leiomyomatosis and Renal Cell Carcinoma" /><meta name="citation_keywords" content="Fumarate hydratase, mitochondrial" /><meta name="citation_keywords" content="FH" /><meta name="citation_keywords" content="Hereditary Leiomyomatosis and Renal Cell Cancer" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Hereditary Leiomyomatosis and Renal Cell Cancer" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Manop Pithukpakorn" /><meta name="DC.Contributor" content="Jorge R Toro" /><meta name="DC.Date" content="2015/08/06" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1252/" /><meta name="description" content="Hereditary leiomyomatosis and renal cell cancer (HLRCC) is characterized by cutaneous leiomyomata (multiple or single in 76% of affected individuals), uterine leiomyomata (fibroids), and/or a single renal tumor. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 25 years, increasing in size and number with age. Uterine leiomyomata are present in almost all females with HLRCC and tend to be numerous and large; age at diagnosis ranges from 18 to 52 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors causing hematuria, lower back pain, and a palpable mass are usually unilateral, solitary, and aggressive and range from type 2 papillary to tubulo-papillary to collecting-duct carcinomas. They occur in about 10%-16% of individuals with HLRCC; the median age of detection is 44 years." /><meta name="og:title" content="Hereditary Leiomyomatosis and Renal Cell Cancer" /><meta name="og:type" content="book" /><meta name="og:description" content="Hereditary leiomyomatosis and renal cell cancer (HLRCC) is characterized by cutaneous leiomyomata (multiple or single in 76% of affected individuals), uterine leiomyomata (fibroids), and/or a single renal tumor. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 25 years, increasing in size and number with age. Uterine leiomyomata are present in almost all females with HLRCC and tend to be numerous and large; age at diagnosis ranges from 18 to 52 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors causing hematuria, lower back pain, and a palpable mass are usually unilateral, solitary, and aggressive and range from type 2 papillary to tubulo-papillary to collecting-duct carcinomas. They occur in about 10%-16% of individuals with HLRCC; the median age of detection is 44 years." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1252/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/hlrcc/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1252/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8929ACE03F633100000000093E0383.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1252_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1252_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hht/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/accpn/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1252_"><span class="title" itemprop="name">Hereditary Leiomyomatosis and Renal Cell Cancer</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: HLRCC</div><p class="contrib-group"><span itemprop="author">Manop Pithukpakorn</span>, MD and <span itemprop="author">Jorge R Toro</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1252_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1252_ai__"><div class="contrib half_rhythm"><span itemprop="author">Manop Pithukpakorn</span>, MD<div class="affiliation small">Division of Medical Genetics<br />Department of Medicine<br />Faculty of Medicine<br />Siriraj Hospital<br />Mahidol University<br />Bangkok, Thailand<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ht.ca.lodiham@tip.ponam" class="oemail">ht.ca.lodiham@tip.ponam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jorge R Toro</span>, MD<div class="affiliation small">Genetic Epidemiology Branch<br />Division of Cancer Epidemiology and Genetics<br />National Cancer Institute<br />National Institutes of Health<br />Dermatology Section<br />DCVA Medical Center<br />Washington, DC<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@ojorot" class="oemail">vog.hin.liam@ojorot</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">July 31, 2006</span>; Last Update: <span itemprop="dateModified">August 6, 2015</span>.</p><p><em>Estimated reading time: 21 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="hlrcc.Summary" itemprop="description"><h2 id="_hlrcc_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Hereditary leiomyomatosis and renal cell cancer (HLRCC) is characterized by cutaneous leiomyomata (multiple or single in 76% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals), uterine leiomyomata (fibroids), and/or a single renal tumor. Cutaneous leiomyomata appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face, and appear at a mean age of 25 years, increasing in size and number with age. Uterine leiomyomata are present in almost all females with HLRCC and tend to be numerous and large; age at diagnosis ranges from 18 to 52 years, with most women experiencing irregular or heavy menstruation and pelvic pain. Renal tumors causing hematuria, lower back pain, and a palpable mass are usually unilateral, solitary, and aggressive and range from type 2 papillary to tubulo-papillary to collecting-duct carcinomas. They occur in about 10%-16% of individuals with HLRCC; the median age of detection is 44 years.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of HLRCC is established with the identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FH</i> in combination with multiple cutaneous leiomyomas, with at least one histologically confirmed leiomyoma, a single leiomyoma in the presence of a positive family history of HLRCC, and/or one or more tubulo-papillary, collecting-duct, or papillary type 2 renal tumors with or without a family history of HLRCC. Testing of fumarate hydratase enzyme activity is an alternative in those with atypical presentation and an undetectable FH pathogenic variant.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Surgical excision, cryoablation, and/or laser excision to remove painful cutaneous leiomyomas; pain medication includes calcium channel blockers, alpha blockers, nitroglycerin, antidepressants, or antiepileptic drugs. Treatment of uterine fibroids can include gonadotropin-releasing hormone agonists, antihormonal medications, pain relievers, myomectomy, and hysterectomy. Total nephrectomy should be considered in individuals with kidney tumors.</p><p><i>Surveillance:</i> For <i>FH</i> heterozygotes and at-risk family members who have not undergone <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>: every one to two years full skin examination to evaluate for changes suggestive of leiomyosarcoma; annual gynecologic consultation to assess severity of uterine fibroids and to evaluate for changes suggestive of leiomyosarcoma; yearly examination with abdominal MRI for individuals with normal initial baseline or follow-up scans; once a renal lesion is identified, CT scan with and without contrast and renal ultrasound examination, PET-CT scan to identify metabolically active lesions, and evaluation by a urologic oncology surgeon familiar with the renal cancer of HLRCC.</p><p><i>Evaluation of relatives at risk:</i> When the <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of asymptomatic at-risk relatives improves diagnostic certainty and allows early surveillance and treatment. If the pathogenic variant in the family is not known, fumarate hydratase enzyme assay can be used to clarify the disease status of at-risk relatives.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>HLRCC is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. If a parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has an <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the sibs of the proband have a 50% chance of inheriting the pathogenic variant. Each child of an individual with HLRCC has a 50% chance of inheriting the pathogenic variant. The degree of clinical severity is not predictable. Prenatal testing for pregnancies at increased risk is possible if the pathogenic variant in a family is known.</p></div></div><div id="hlrcc.Diagnosis"><h2 id="_hlrcc_Diagnosis_">Diagnosis</h2><div id="hlrcc.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Hereditary leiomyomatosis and renal cell cancer (HLRCC) <b>should be suspected</b> in individuals with one or more of the following major features:</p><p><b>Cutaneous leiomyomata.</b> The majority (76%) of individuals with HLRCC present with a single or multiple cutaneous leiomyomata.</p><p>Clinically, cutaneous leiomyomas appear as skin-colored to light brown papules or nodules distributed over the trunk and extremities, and occasionally on the face. The different presentations include: single, grouped/clustered, segmental, and disseminated. 40% of individuals with HLRCC have mild cutaneous manifestations with five or fewer lesions [<a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al 2006</a>].</p><p>Histologically, proliferation of interlacing bundles of smooth muscle fibers with centrally located, long blunt-edged nuclei is observed.</p><p><b>Uterine leiomyomata (uterine fibroids).</b> Uterine leiomyomas are present in almost all females with HLRCC [<a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>, <a class="bk_pop" href="#hlrcc.REF.alam.2005.199">Alam et al 2005</a>, <a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al 2006</a>]. Fibroids tend to be numerous and large. In females the presence of cutaneous leiomyomata correlates with the presence of uterine fibroids [<a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>, <a class="bk_pop" href="#hlrcc.REF.alam.2005.199">Alam et al 2005</a>, <a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al 2006</a>].</p><p><b>Renal tumors.</b> 10%-16% of individuals with HLRCC have renal tumors [<a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>, <a class="bk_pop" href="#hlrcc.REF.alam.2005.199">Alam et al 2005</a>]. Most tumors are classified as 'type 2' papillary renal cancer, displaying a distinct papillary architecture and characteristic histopathology [<a class="bk_pop" href="#hlrcc.REF.launonen.2001.3387">Launonen et al 2001</a>, <a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>]. Other types of renal tumors reported include a spectrum of tumors from tubulo-papillary renal cell carcinomas to collecting-duct renal cell carcinomas [<a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>, <a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al 2006</a>].</p></div><div id="hlrcc.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>For individuals or families with suspected clinical phenotypes, <b>clinical diagnosis</b> of HLRCC should be considered as follows:</p><p><b>Major criterion.</b> Histopathologically confirmed multiple cutaneous leiomyomas</p><p><b>Minor criteria</b></p><ul><li class="half_rhythm"><div>Surgery required; symptomatic and/or multiple uterine leiomyomas before age 40 years</div></li><li class="half_rhythm"><div>Type 2 papillary renal cell carcinoma before age 40 years</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> who meets one of the above criteria</div></li></ul><p>The diagnosis is likely when an individual meets the major criterion; HLRCC may be suspected when an individual meets at least two minor criteria [<a class="bk_pop" href="#hlrcc.REF.smit.2011.49">Smit et al 2011</a>].</p><p>The diagnosis of HLRCC <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FH</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1252/table/hlrcc.T.molecular_genetic_testing_used_i/?report=objectonly" target="object" rid-figpopup="fighlrccTmoleculargenetictestingusedi" rid-ob="figobhlrccTmoleculargenetictestingusedi">Table 1</a>) <b>in combination with</b> the following clinical findings:</p><ul><li class="half_rhythm"><div>Multiple cutaneous leiomyomas (with &#x02265;1 histologically confirmed leiomyoma) without a family history of HLRCC</div></li><li class="half_rhythm"><div>A single cutaneous leiomyoma with family history of HLRCC</div></li><li class="half_rhythm"><div>One or more tubulo-papillary, collecting-duct, or papillary type 2 renal tumors with or without a family history of HLRCC</div></li></ul><p>Note: (1) Because the prevalence of uterine leiomyomas in the general population is high, a solitary uterine leiomyoma even in the presence of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is not sufficient for the diagnosis of HLRCC. (2) Measurement of fumarate hydratase enzyme activity can be useful in the diagnosis of HLRCC in cases with atypical presentation and undetectable <i>FH</i> pathogenic variants [<a class="bk_pop" href="#hlrcc.REF.alam.2003.1241">Alam et al 2003</a>, <a class="bk_pop" href="#hlrcc.REF.pithukpakorn.2006.755">Pithukpakorn et al 2006</a>]. Reduced activity (&#x02264;60%) of fumarate hydratase enzyme was found in all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with the diagnosis of HLRCC.</p><p>Molecular testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>FH</i> is performed first, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>FH</i> and other genes of interest (see <a href="#hlrcc.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="hlrcc.T.molecular_genetic_testing_used_i" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in HLRCC</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1252/table/hlrcc.T.molecular_genetic_testing_used_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlrcc.T.molecular_genetic_testing_used_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlrcc.T.molecular_genetic_testing_used_i_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_hlrcc.T.molecular_genetic_testing_used_i_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_hlrcc.T.molecular_genetic_testing_used_i_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_hlrcc.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>FH</i></td><td headers="hd_h_hlrcc.T.molecular_genetic_testing_used_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_hlrcc.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">70%-90%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_hlrcc.T.molecular_genetic_testing_used_i_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_hlrcc.T.molecular_genetic_testing_used_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1/20&#x000a0;<sup>6</sup>-1/7&#x000a0;<sup>7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="hlrcc.TF.1.1"><p class="no_margin">See <a href="/books/NBK1252/#hlrcc.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="hlrcc.TF.1.2"><p class="no_margin">See <a href="#hlrcc.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="hlrcc.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="hlrcc.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al [2003]</a>, <a class="bk_pop" href="#hlrcc.REF.alam.2005.199">Alam et al [2005]</a>, <a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al [2006]</a>, <a class="bk_pop" href="#hlrcc.REF.gardie.2011.226">Gardie et al [2011]</a>, <a class="bk_pop" href="#hlrcc.REF.smit.2011.49">Smit et al [2011]</a></p></div></dd><dt>5. </dt><dd><div id="hlrcc.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used can include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="hlrcc.TF.1.6"><p class="no_margin"><a class="bk_pop" href="#hlrcc.REF.smit.2011.49">Smit et al [2011]</a></p></div></dd><dt>7. </dt><dd><div id="hlrcc.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#hlrcc.REF.ahvenainen.2008.83">Ahvenainen et al [2008]</a></p></div></dd></dl></div></div></div></div></div><div id="hlrcc.Clinical_Characteristics"><h2 id="_hlrcc_Clinical_Characteristics_">Clinical Characteristics</h2><div id="hlrcc.Clinical_Description"><h3>Clinical Description</h3><p>The clinical characteristics of hereditary leiomyomatosis and renal cell cancer (HLRCC) include cutaneous leiomyomas, uterine leiomyomata (fibroids), and/or renal tumors. Affected individuals may have multiple cutaneous leiomyomas, a single skin leiomyoma, or no cutaneous lesion; a single renal tumor or no renal tumors; and/or uterine fibroids. Disease severity shows significant intra- and interfamilial variation [<a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al 2006</a>].</p><p><b>Cutaneous leiomyomata.</b> Clinically, cutaneous leiomyomas present as firm skin-colored to light brown-colored papules and nodules. These cutaneous lesions occur at a mean age of 25 years (range: age 10-47 years) and tend to increase in size and number with age. Affected individuals note that the skin lesions are sensitive to light touch and/or cold temperature and, less commonly, are painful.</p><p>Histologically, proliferation of interlacing bundles of smooth muscle fibers with centrally located, long blunt-edged nuclei is observed.</p><p><b>Uterine fibroids.</b> Women with HLRCC have more uterine fibroids and onset at a younger age than women in the general population. The age at diagnosis ranges from 18 to 52 years (mean: age 30 years). Uterine leiomyomas are usually large and numerous. Most women experience irregular or heavy menstruation and pelvic pain. Women with HLRCC and uterine fibroids undergo hysterectomy or myomectomy for symptomatic uterine fibroids at a younger age (&#x0003c;30 years) than the general population (45 years) [<a class="bk_pop" href="#hlrcc.REF.farquhar.2002.229">Farquhar &#x00026; Steiner 2002</a>, <a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>, <a class="bk_pop" href="#hlrcc.REF.alam.2005.199">Alam et al 2005</a>].</p><p><b>Renal cancer.</b> The symptoms of renal cancer may include hematuria, lower back pain, and a palpable mass. However, a large number of individuals with renal cancer are asymptomatic. Furthermore, not all individuals with HLRCC present with or develop renal cancer.</p><p>Most renal tumors are unilateral and solitary; in a few individuals, they are multifocal. Approximately 10%-16% of individuals with HLRCC who present with multiple cutaneous leiomyomas had renal tumors at the time that renal imaging was performed [<a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>, <a class="bk_pop" href="#hlrcc.REF.alam.2005.199">Alam et al 2005</a>]. The median age at detection of renal tumors is 44 years. In contrast to other hereditary renal cancer syndromes, renal cancers associated with HLRCC are aggressive, with nine of 13 individuals dying from metastatic disease within five years of diagnosis [<a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>].</p><p>The renal tumors associated with HLRCC have unique histologic features, including the presence of cells with abundant amphophilic cytoplasm and large nuclei with large inclusion-like eosinophilic nucleoli. These cytologic features were attributed to type 2 papillary tumors in the original description. However, recent studies have shown that HLRCC is associated with a spectrum of renal tumors ranging from type 2 papillary to tubulo-papillary to collecting-duct carcinoma [<a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al 2006</a>]. Renal tumors associated with HLRCC may, in the future, constitute a new renal pathologic entity.</p><p><b>Uterine leiomyosarcoma.</b> Whether all women with HLRCC are at a higher risk of developing uterine leiomyosarcomas is unclear. In the original description of HLRCC, it was reported that two of 11 women with uterine leiomyomas also had uterine leiomyosarcoma, a cancer that may be aggressive if not detected and treated at an early stage [<a class="bk_pop" href="#hlrcc.REF.launonen.2001.3387">Launonen et al 2001</a>]. Six women with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> and uterine leiomyosarcoma have been reported [<a class="bk_pop" href="#hlrcc.REF.lehtonen.2006.523">Lehtonen et al 2006</a>, <a class="bk_pop" href="#hlrcc.REF.ylisaukkooja.2006.283">Ylisaukko-oja et al 2006</a>]. However, studies from other cohorts showed no reported leiomyosarcoma among women with germline <i>FH</i> pathogenic variants and no germline <i>FH</i> pathogenic variants in three women with uterine leiomyosarcomas and/or family history of uterine leiomyosarcomas [<a class="bk_pop" href="#hlrcc.REF.gardie.2011.226">Gardie et al 2011</a>, <a class="bk_pop" href="#hlrcc.REF.smit.2011.49">Smit et al 2011</a>]. It appears that individuals/families with a germline <i>FH</i> pathogenic variant are, in general, not highly predisposed to uterine cancer; but a few individuals and families appear to be at high risk. In North America, no individuals or families with HLRCC and uterine leiomyosarcomas have been reported. Therefore, the risk to women with HLRCC of developing uterine leiomyosarcoma is unknown.</p><p><b>Other.</b> Four individuals with breast cancer as well as individuals with bladder cancer, bilateral macronodular adrenocortical disease and atypical Cushing syndrome, adrenal incidentaloma, Leydig-cell tumors of the testis and ovarian cystadenomas, and gastrointestinal stromal tumors (GISTs) have been reported; it remains to be determined whether these manifestations are truly associated with HLRCC [<a class="bk_pop" href="#hlrcc.REF.alam.2005.199">Alam et al 2005</a>, <a class="bk_pop" href="#hlrcc.REF.lamba.2005.332">Lamba et al 2005</a>, <a class="bk_pop" href="#hlrcc.REF.matyakhina.2005.3773">Matyakhina et al 2005</a>, <a class="bk_pop" href="#hlrcc.REF.carvajalcarmona.2006.3071">Carvajal-Carmona et al 2006</a>, <a class="bk_pop" href="#hlrcc.REF.lehtonen.2006.523">Lehtonen et al 2006</a>, <a class="bk_pop" href="#hlrcc.REF.smit.2011.49">Smit et al 2011</a>].</p></div><div id="hlrcc.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been described.</p><p>No correlation is observed between specific <i>FH</i> pathogenic variants and the occurrence of cutaneous lesions, uterine fibroids, or renal cancer of HLRCC [<a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al 2006</a>].</p><p><i>FH</i> pathogenic variants associated with HLRCC are distributed throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> rather than clustering at the amino terminal of <i>FH</i>. The predisposition to HLRCC versus <a href="/books/n/gene/fum/">fumarase deficiency</a> likely results from a difference in gene dosage rather than the location of the <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> as originally suggested [<a class="bk_pop" href="#hlrcc.REF.tomlinson.2002.406">Tomlinson et al 2002</a>].</p></div><div id="hlrcc.Penetrance"><h3>Penetrance</h3><p>Based on three major clinical manifestations, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of HLRCC is considered to be very high. However, an asymptomatic individual who was an <a class="def" href="/books/n/gene/glossary/def-item/obligate-heterozygote/">obligate heterozygote</a> for a <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in one family has been reported [<a class="bk_pop" href="#hlrcc.REF.gardie.2011.226">Gardie et al 2011</a>].</p></div><div id="hlrcc.Nomenclature"><h3>Nomenclature</h3><p>Historically, the predisposition to the development of cutaneous leiomyomas was referred to as multiple cutaneous leiomyomatosis (MCL).</p><p><a class="bk_pop" href="#hlrcc.REF.reed.1973.409">Reed et al [1973]</a> described two kindreds in which multiple members over three generations exhibited cutaneous leiomyomas and uterine leiomyomas and/or leiomyosarcomas inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> pattern. In this report, they also described a woman age 20 years with uterine leiomyosarcoma and metastatic renal cancer. Since then, the association of cutaneous and uterine leiomyomas has been refered to as Reed's syndrome.</p><p>The clear association of cutaneous leiomyomas and kidney cancer was not described until <a class="bk_pop" href="#hlrcc.REF.launonen.2001.3387">Launonen et al [2001]</a> reported two Finnish families in which cutaneous and uterine leiomyomas and papillary type 2 renal cell carcinoma co-segregated. The name hereditary leiomyomatosis and renal cell cancer (HLRCC) was designated, and the disorder was assigned OMIM number <a href="http://omim.org/entry/605839" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">605839</a>. The term &#x02018;hereditary leiomyomatosis and renal cell cancer&#x02019; is preferred because among individuals with cutaneous leiomyomas it is impossible to distinguish between those at and those not at increased risk for renal cancer.</p></div><div id="hlrcc.Prevalence"><h3>Prevalence</h3><p>More than 300 families with HLRCC from various populations have been described.</p></div></div><div id="hlrcc.Genetically_Related_Allelic_Disord"><h2 id="_hlrcc_Genetically_Related_Allelic_Disord_">Genetically Related (Allelic) Disorders</h2><p><a href="/books/n/gene/fum/"><b>Fumarase deficiency</b></a>
<b>(fumaric aciduria).</b> Fumarase deficiency, resulting from inherited <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> variants in <i>FH</i>, is an inborn error of metabolism characterized by rapidly progressive neurologic impairment including hypotonia, seizures, and cerebral atrophy. Homozygous or <a class="def" href="/books/n/gene/glossary/def-item/compound-heterozygous/">compound heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>FH</i> pathogenic variants are causative [<a class="bk_pop" href="#hlrcc.REF.coughlin.1998.254">Coughlin et al 1998</a>]. Leiomyomas and renal cancer have not been reported in fumaric aciduria. However, most individuals with fumaric aciduria survive only a few months; a very few survive to early adulthood. A parent (heterozygous <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>) of an individual with fumarase deficiency developed cutaneous leiomyomata similar to those observed in HLRCC [<a class="bk_pop" href="#hlrcc.REF.tomlinson.2002.406">Tomlinson et al 2002</a>]. The death from renal cancer of the mother of a child with fumaric aciduria supports the increased risk for HLRCC in the heterozygous relatives of children with fumaric aciduria [Shih, unpublished]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p><b>Somatic mutation.</b> Loss of heterozygosity around the <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> has been identified in two early-onset <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> uterine leiomyomas and a soft tissue sarcoma of the lower limb without other associated tumors characteristic of the heritable disease [<a class="bk_pop" href="#hlrcc.REF.kiuru.2002.4554">Kiuru et al 2002</a>, <a class="bk_pop" href="#hlrcc.REF.lehtonen.2004.17">Lehtonen et al 2004</a>]. All three tumors displayed <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> inactivation of <i>FH</i>.</p></div><div id="hlrcc.Differential_Diagnosis"><h2 id="_hlrcc_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Cutaneous lesions.</b> Cutaneous leiomyomas are rare and particular to hereditary leiomyomatosis and renal cell cancer (HLRCC). Because leiomyomas are clinically similar to various cutaneous lesions, histologic diagnosis is required.</p><p><b>Uterine fibroids.</b> Uterine leiomyoma is the most common benign pelvic tumor in women in the general population. The majority of uterine fibroids are <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> and nonsyndromic.</p><p><b>Renal tumor.</b> Familial renal cancer syndromes (see <a class="figpopup" href="/books/NBK1252/table/hlrcc.T.familial_renal_cancer_syndrome_c/?report=objectonly" target="object" rid-figpopup="fighlrccTfamilialrenalcancersyndromec" rid-ob="figobhlrccTfamilialrenalcancersyndromec">Table 2</a> for comparison) are associated with rather specific renal pathology. Familial renal cancer syndromes and their specific renal pathology include:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/vhl/"><b>Von Hippel-Lindau (VHL) syndrome</b></a><b>.</b> Clear cell renal cell carcinoma. Individuals with VHL syndrome are also at risk for CNS hemangioblastoma, retinal angioma, pheochromocytoma, and endolymphatic sac tumors. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/bhd/"><b>Birt-Hogg-Dub&#x000e9; syndrome</b></a>
<b>(BHDS).</b> A spectrum of renal tumors including renal oncocytoma (benign), chromophobe renal cell carcinoma (malignant), and a combination of both cell types, so-called oncocytic hybrid tumor. Individuals with BHDS can present with cutaneous fibrofolliculomas and/or with multiple lung cysts and spontaneous pneumothorax. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li><li class="half_rhythm"><div><b>Hereditary papillary renal cancer (HPRC)</b> (OMIM <a href="http://omim.org/entry/605074" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">605074</a>). Predisposition to type 1 papillary renal cancer. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>.</div></li></ul><div id="hlrcc.T.familial_renal_cancer_syndrome_c" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Familial Renal Cancer Syndrome Comparisons</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1252/table/hlrcc.T.familial_renal_cancer_syndrome_c/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlrcc.T.familial_renal_cancer_syndrome_c_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Condition</th><th id="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Renal Tumor</th><th id="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cutaneous Lesions</th><th id="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Uterine Fibroids</th><th id="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Other Common Findings</th></tr></thead><tbody><tr><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HLRCC</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Papillary type 2 RCC</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cutaneous leiomyoma</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Early onset; multiple lesions</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td></tr><tr><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/vhl/">VHL syndrome</a></td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clear cell RCC</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">CNS hemangioblastoma, retinal angioma, renal cysts, pancreatic cysts, pancreatic tumor, pheochromocytoma</td></tr><tr><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/bhd/">BHDS</a></td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Various: oncocytoma, chromophobe RCC, hybrid chromophobe/oncocytic tumor</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cutaneous fibrofolliculoma, trichodiscoma, acrochordon</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple lung cysts</td></tr><tr><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">HPRC</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Papillary type 1 RCC</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td><td headers="hd_h_hlrcc.T.familial_renal_cancer_syndrome_c_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">RCC = renal cell carninoma</p></div></dd><dt></dt><dd><div><p class="no_margin">CNS = central nervous system</p></div></dd></dl></div></div></div></div><div id="hlrcc.Management"><h2 id="_hlrcc_Management_">Management</h2><div id="hlrcc.Evaluations_Following_Initial_Diag"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with hereditary leiomyomatosis and renal cell cancer (HLRCC), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Detailed dermatologic examination for evaluation of extent of disease and lesions suspicious for cutaneous leiomyosarcoma to include biopsy for histologic confirmation</div></li><li class="half_rhythm"><div>Baseline pelvic bimanual examination, pelvic MRI, and/or transvaginal pelvic ultrasound examination to screen for uterine fibroids</div></li><li class="half_rhythm"><div>Baseline renal ultrasound examination and MRI to screen for renal tumors; abdominal CT scan with contrast should be reserved for when MRI is contraindicated</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="hlrcc.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Cutaneous lesions.</b> Cutaneous leiomyomas should be examined by a dermatologist. Treatment of cutaneous leiomyomas is difficult:</p><ul><li class="half_rhythm"><div>Surgical excision may be performed for a solitary painful lesion.</div></li><li class="half_rhythm"><div>Lesions can be treated by cryoablation and/or lasers.</div></li><li class="half_rhythm"><div>Several medications, including calcium channel blockers, alpha blockers, nitroglycerin, antidepressants, and antiepileptic drugs (AEDs), have been reported to reduce pain [<a class="bk_pop" href="#hlrcc.REF.ritzmann.2006.84">Ritzmann et al 2006</a>].</div></li></ul><p><b>Uterine fibroids</b> should be evaluated by a gynecologist. The uterine fibroids of HLRCC are treated in the same manner as <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> fibroids. However, most women with HLRCC may require medical and/or surgical intervention earlier than the general population. Medical therapy (currently including gonadotropin-releasing hormone agonists [GnRHa], antihormonal medications, and pain relievers) may be used initially to treat uterine fibroids, to decrease the size of fibroids in preparation for surgical removal, and/or to provide temporary relief from the symptoms of fibroids. When possible, myomectomy to remove fibroids while preserving the uterus is the treatment of choice. Hysterectomy should be performed only when necessary.</p><p><b>Renal tumors.</b> Early detection of kidney tumor in HLRCC is important. Surgical excision of these malignancies appears to require earlier and more extensive surgery than other hereditary kidney cancers. Further studies may demonstrate that even small tumors have a high grade of malignancy on pathologic review. Kidney tumors associated with HLRCC have an aggressive disease course. Therefore, these tumors must be managed with caution until more is known about the natural history. Because of the aggressive nature of renal cancers associated with HLRCC, total nephrectomy should be strongly considered in individuals with a detectable renal mass.</p></div><div id="hlrcc.Surveillance"><h3>Surveillance</h3><p>There is no consensus on clinical surveillance; the following recommendations are provisional until a consensus conference is conducted.</p><p>Individuals with the clinical diagnosis of HLRCC, individuals with <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> pathogenic variants in <i>FH</i> without clinical manifestations, and at-risk family members who have not undergone <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> should have the following regular surveillance by physicians familiar with the clinical manifestations of HLRCC.</p><p><b>Skin.</b> Full skin examination is recommended annually to every two years to assess the extent of disease and to evaluate for changes suggestive of leiomyosarcoma.</p><p><b>Uterus.</b> Annual gynecologic consultation is recommended to assess severity of uterine fibroids and to evaluate for changes suggestive of leiomyosarcoma.</p><p><b>Renal</b></p><ul><li class="half_rhythm"><div>Yearly examination with abdominal MRI is recommended for individuals with normal initial baseline or follow-up abdominal MRI. MRI is preferred because of the potential added radiation exposure associated with CT over lifetime. Abdominal CT scan with contrast should be reserved for when MRI is contraindicated.</div></li><li class="half_rhythm"><div>Any suspicious renal lesion (indeterminate lesion, questionable or complex cysts) detected at a previous examination should be followed with a CT scan with and without contrast. The use of renal ultrasound examination is helpful in the characterization of cystic lesions. PET-CT may be added to identify metabolically active lesions suggesting possible malignant growth. Caution: Ultrasound examination alone is never sufficient.</div></li><li class="half_rhythm"><div>Renal tumors should be evaluated by a urologic oncology surgeon familiar with the renal cancer of HLRCC.</div></li></ul></div><div id="hlrcc.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate relatives at risk in order to identify as early as possible those who would benefit from initiation of treatment and preventive measures.</p><ul><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of asymptomatic at-risk relatives improves diagnostic certainty, allows early surveillance and treatment in those with the family-specific pathogenic variant, and reduces costly screening procedures in those who have not inherited the pathogenic variant.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family is not known, fumarate hydratase enzyme assay can be used to clarify the disease status of at-risk relatives. Early recognition of clinical manifestations may allow timely intervention and improve outcome. Therefore, clinical surveillance of asymptomatic at-risk relatives for early detection is appropriate.</div></li></ul><p>See <a href="#hlrcc.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes</p></div><div id="hlrcc.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Several studies of anti-VEGF and novel tyrosine kinase inhibitor treatment in HLRCC and papillary RCC (including papillary type 2 RCC) have been conducted [<a class="bk_pop" href="#hlrcc.REF.linehan.2013.3345">Linehan &#x00026; Rouault 2013</a>]. Early report demonstrated improvement of progression-free survival in patients with papillary type 2 RCC with Sunitinib [<a class="bk_pop" href="#hlrcc.REF.choueiri.2008.127">Choueiri et al 2008</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT01130519" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Clinical Trials</a>].</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions</p></div></div><div id="hlrcc.Genetic_Counseling"><h2 id="_hlrcc_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="hlrcc.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Hereditary leiomyomatosis and renal cell cancer (HLRCC) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="hlrcc.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Some individuals diagnosed with HLRCC have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, and some have HLRCC as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>
<i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>The proportion of cases caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is unknown because subtle manifestation in parents has not been evaluated and genetic testing data are insufficient.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, two possible explanations are <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent or a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</div></li><li class="half_rhythm"><div>Recommendations for evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> if the <i>FH</i> pathogenic variant in the proband has been identified.</div></li><li class="half_rhythm"><div>The family history of some individuals diagnosed with HLRCC may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate evaluations (e.g., <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>) have been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is clinically <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has an <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, each sib of the proband is at a 50% risk of inheriting the pathogenic variant.</div></li><li class="half_rhythm"><div>If the <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low but greater than that of the general population because of the possibility of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with HLRCC has a 50% chance of inheriting the <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. The degree of clinical severity is not predictable.</p><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk to other family members depends on the status of the proband's parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or has a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members are at risk.</p></div><div id="hlrcc.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#hlrcc.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment</p><p><b>Predicting the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> in individuals who have inherited a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> It is not possible to predict whether symptoms will occur, or if they do, what the age of onset, severity and type of symptoms, or rate of disease progression will be in individuals who have a pathogenic variant.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with HLRCC has the pathogenic variant or clinical evidence of the disorder, the <i>FH</i> variant is likely <i>de novo</i>. However, possible non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p><p><b>Testing at-risk asymptomatic family members.</b> Molecular genetic testing of at-risk family members is appropriate in order to identify the need for clinical surveillance. Interpretation of the result is most accurate when a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member. Those who have a pathogenic variant require regular lifelong surveillance. Family members who have not inherited the pathogenic variant and their offspring have risks similar to the general population.</p><p>Early detection of at-risk individuals affects medical management. However, in the absence of an increased risk of developing childhood malignancy, the American Society of Clinical Oncology recommends delaying genetic testing in at-risk individuals during childhood until individuals reach age 18 years and are able to make informed decisions regarding genetic testing [<a class="bk_pop" href="#hlrcc.REF1">American Society of Clinical Oncology 2003</a>].</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="hlrcc.Prenatal_Testing_and_Preimplantati"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>FH</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="hlrcc.Resources"><h2 id="_hlrcc_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>HLRCC Family Alliance</b></div><div>2001 Beacon Street</div><div>Suite 208</div><div>Boston MA 02135-7787</div><div><b>Phone:</b> 617-277-5667 ext. 709; 800-767-4845 ext. 709 (toll-free)</div><div><b>Fax:</b> 858-712-8712; 866-209-0288 (toll-free)</div><div><b>Email:</b> hlrcc@vhl.org</div><div><a href="http://www.hlrccinfo.org/index.php" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hlrccinfo.org</a></div></li><li class="half_rhythm"><div><b>Kidney Cancer Association</b></div><div>PO Box 96503</div><div>Washington DC 20090</div><div><b>Phone:</b> 800-850-9132 (toll-free); 312-436-1455</div><div><b>Fax:</b> 847-332-2978</div><div><b>Email:</b> kidney.cancer@hotmail.com</div><div><a href="http://www.kidneycancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.kidneycancer.org</a></div></li><li class="half_rhythm"><div><b>National Uterine Fibroids Foundation (NUFF)</b></div><div>PO Box 9688</div><div>Colorado Springs CO 80932-0688</div><div><b>Phone:</b> 800-874-7247 (toll-free); 719-633-3454</div><div><b>Email:</b> info@NUFF.org</div><div><a href="http://www.nuff.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nuff.org</a></div></li></ul></div><div id="hlrcc.Molecular_Genetics"><h2 id="_hlrcc_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="hlrcc.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Hereditary Leiomyomatosis and Renal Cell Cancer: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1252/table/hlrcc.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlrcc.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_hlrcc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_hlrcc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_hlrcc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_hlrcc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_hlrcc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_hlrcc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_hlrcc.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2271" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FH</i></a></td><td headers="hd_b_hlrcc.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2271" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q43</a></td><td headers="hd_b_hlrcc.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P07954" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fumarate hydratase, mitochondrial</a></td><td headers="hd_b_hlrcc.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.LOVD.nl/FH" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TCA Cycle Gene Mutation Database (FH)</a></td><td headers="hd_b_hlrcc.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FH" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FH</a></td><td headers="hd_b_hlrcc.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FH[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FH</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="hlrcc.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="hlrcc.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Hereditary Leiomyomatosis and Renal Cell Cancer (<a href="/omim/136850,150800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1252/table/hlrcc.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlrcc.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/136850" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">136850</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FUMARATE HYDRATASE; FH</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/150800" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">150800</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER; HLRCC</td></tr></tbody></table></div></div><div id="hlrcc.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>Germline pathogenic variants in <i>FH</i>, plus somatic variants and <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a> in tumor tissue, suggest that loss of function of the fumarate hydratase protein is the basis of tumor formation in HLRCC [<a class="bk_pop" href="#hlrcc.REF.tomlinson.2002.406">Tomlinson et al 2002</a>]. Intracellular fumarate accumulation as a result of <i>FH</i> inactivation causes decreased hypoxia-inducible factor (HIF) degradation and overexpression of genes further downstream in the HIF pathway [<a class="bk_pop" href="#hlrcc.REF.isaacs.2005.143">Isaacs et al 2005</a>]. <i>FH</i>-associated neoplasia is characterized by defective mitochondrial function and by upregulation of transcriptional pathways mediated by HIF, although it has been disputed whether and by what means these processes are linked. Upregulation of HIF-1&#x003b1; occurs as a direct consequence of <i>FH</i> inactivation. The upregulation of HIF-1&#x003b1; arises from competitive inhibition of the 2-OG-dependent HIF hydroxylases by fumarate and not from disruption of mitochondrial energy metabolism [<a class="bk_pop" href="#hlrcc.REF.oflaherty.2010.3844">O'Flaherty et al 2010</a>].</p><p><b>Gene structure.</b>
<i>FH</i> consists of ten exons encompassing 22.15 kb of DNA. The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> is highly conserved across species. For a detailed summary of gene and protein information, see <a href="/books/NBK1252/#hlrcc.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> Various <i>FH</i> pathogenic variants have been identified in families with HLRCC. Most are <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants; others are <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, and splice-site variants [<a class="bk_pop" href="#hlrcc.REF.tomlinson.2002.406">Tomlinson et al 2002</a>, <a class="bk_pop" href="#hlrcc.REF.toro.2003.95">Toro et al 2003</a>, <a class="bk_pop" href="#hlrcc.REF.wei.2006.18">Wei et al 2006</a>].</p><p>Evidence for a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a> has been observed for the 905-1G&#x0003e;A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in four families of Jewish Iranian origin, the c.302G&#x0003e;C pathogenic variant in a German and English family, and the p.Glu404Ter pathogenic variant in three families in the same province in the Netherlands [<a class="bk_pop" href="#hlrcc.REF.chan.2005.75">Chan et al 2005</a>, <a class="bk_pop" href="#hlrcc.REF.chuang.2005.410">Chuang et al 2005</a>, <a class="bk_pop" href="#hlrcc.REF.heinritz.2008.35">Heinritz et al 2008</a>, <a class="bk_pop" href="#hlrcc.REF.smit.2011.49">Smit et al 2011</a>].</p><p>Four whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions have been identified [<a class="bk_pop" href="#hlrcc.REF.ahvenainen.2008.83">Ahvenainen et al 2008</a>, <a class="bk_pop" href="#hlrcc.REF.smit.2011.49">Smit et al 2011</a>]. For more information, see <a href="/books/NBK1252/#hlrcc.molgen.TA">Table A</a>, <b>Locus-Specific Databases</b>.</p><div id="hlrcc.T.fh_pathogenic_variants_discussed" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>FH</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1252/table/hlrcc.T.fh_pathogenic_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__hlrcc.T.fh_pathogenic_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias)&#x000a0;<sup>1</sup></th><th id="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias)&#x000a0;<sup>1</sup></th><th id="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.905-1G&#x0003e;A</td><td headers="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_3" rowspan="3" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000143.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000143<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/protein/NP_000134.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000134<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.302G&#x0003e;C&#x000a0;<sup>2</sup><br />(173G&#x0003e;C)</td><td headers="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg101Gln&#x000a0;<sup>2</sup><br />(Gly58Ala)</td></tr><tr><td headers="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1210G&#x0003e;T</td><td headers="hd_h_hlrcc.T.fh_pathogenic_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu404Ter</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="hlrcc.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="hlrcc.TF.3.2"><p class="no_margin">For nomenclature change see <a href="http://databases.lovd.nl/shared/genes/FH" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">TCA Cycle Gene Mutation Database (FH)</a>.</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>FH</i> encodes the enzyme fumarase (fumarate hydratase) (EC 4.2.1.2.). The active form of the enzyme is a homotetramer. It catalyzes the conversion of fumarate to L-malate in the tricarboxylic acid (Krebs) cycle. The identity between the rat and human amino acid sequences is 96%. In mammals, there are two fumarase <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> (mitochondrial and cytosolic) that are synthesized from the same <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a>. After initial synthesis, the FH proteins are partially imported and processed at the mitochondrial outer membrane. In yeast, approximately 70%-80% of FH proteins are then released back into the cytosol, while the remaining portion is fully imported into mitochondrial matrix [<a class="bk_pop" href="#hlrcc.REF.knox.1998.25587">Knox et al 1998</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Reduced activity of the fumarate hydratase enzyme in cutaneous leiomyomas from individuals with HLRCC supports its role in tumor suppression [<a class="bk_pop" href="#hlrcc.REF.tomlinson.2002.406">Tomlinson et al 2002</a>].</p></div></div><div id="hlrcc.References"><h2 id="_hlrcc_References_">References</h2><div id="hlrcc.Published_Guidelines__Consensus_St"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF1">American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. 2003.</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF2">American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. Available <a href="http://jco.ascopubs.org/content/28/5/893.long" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2010. Accessed 4-17-18.</div></li></ul></div><div id="hlrcc.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.ahvenainen.2008.83">Ahvenainen T, Lehtonen HJ, Lehtonen R, Vahteristo P, Aittom&#x000e4;ki K, Baynam G, Dommering C, Eng C, Gruber SB, Gr&#x000f6;nberg H, Harvima R, Herva R, Hietala M, Kujala M, K&#x000e4;&#x000e4;ri&#x000e4;inen H, Sunde L, Vierimaa O, Pollard PJ, Tomlinson IP, Bj&#x000f6;rck E, Aaltonen LA, Launonen V. Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer. <span><span class="ref-journal">Cancer Genet Cytogenet. </span>2008;<span class="ref-vol">183</span>:83–8.</span> [<a href="/pubmed/18503824" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18503824</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.alam.2005.199">Alam NA, Barclay E, Rowan AJ, Tyrer JP, Calonje E, Manek S, Kelsell D, Leigh I, Olpin S, Tomlinson IP. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. <span><span class="ref-journal">Arch Dermatol. </span>2005;<span class="ref-vol">141</span>:199–206.</span> [<a href="/pubmed/15724016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15724016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.alam.2003.1241">Alam NA, Rowan AJ, Wortham NC, Pollard PJ, Mitchell M, Tyrer JP, Barclay E, Calonje E, Manek S, Adams SJ, Bowers PW, Burrows NP, Charles-Holmes R, Cook LJ, Daly BM, Ford GP, Fuller LC, Hadfield-Jones SE, Hardwick N, Highet AS, Keefe M, MacDonald-Hull SP, Potts ED, Crone M, Wilkinson S, Camacho-Martinez F, Jablonska S, Ratnavel R, MacDonald A, Mann RJ, Grice K, Guillet G, Lewis-Jones MS, McGrath H, Seukeran DC, Morrison PJ, Fleming S, Rahman S, Kelsell D, Leigh I, Olpin S, Tomlinson IP. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. <span><span class="ref-journal">Hum Mol Genet. </span>2003;<span class="ref-vol">12</span>:1241–52.</span> [<a href="/pubmed/12761039" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12761039</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.american_society_of_clinical_oncology.2003.2397">American Society of Clinical Oncology.  Statement on genetic testing for cancer susceptibility. <span><span class="ref-journal">J Cin Oncol. </span>2003;<span class="ref-vol">21</span>:2397–406.</span> [<a href="/pubmed/12692171" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12692171</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.carvajalcarmona.2006.3071">Carvajal-Carmona LG, Alam NA, Pollard PJ, Jones AM, Barclay E, Wortham N, Pignatelli M, Freeman A, Pomplun S, Ellis I, Poulsom R, El-Bahrawy MA, Berney DM, Tomlinson IP. Adult leydig cell tumors of the testis caused by germline fumarate hydratase mutations. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2006;<span class="ref-vol">91</span>:3071–5.</span> [<a href="/pubmed/16757530" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16757530</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.chan.2005.75">Chan I, Wong T, Martinez-Mir A, Christiano AM, McGrath JA. Familial multiple cutaneous and uterine leiomyomas associated with papillary renal cell cancer. <span><span class="ref-journal">Clin Exp Dermatol. </span>2005;<span class="ref-vol">30</span>:75–8.</span> [<a href="/pubmed/15663510" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15663510</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.choueiri.2008.127">Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. <span><span class="ref-journal">J Clin Oncol. </span>2008;<span class="ref-vol">26</span>:127–31.</span> [<a href="/pubmed/18165647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18165647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.chuang.2005.410">Chuang GS, Martinez-Mir A, Geyer A, Engler DE, Glaser B, Cserhalmi-Friedman PB, Gordon D, Horev L, Lukash B, Herman E, Cid MP, Brenner S, Landau M, Sprecher E, Garcia Muret MP, Christiano AM, Zlotogorski A. Germline fumarate hydratase mutations and evidence for a founder mutation underlying multiple cutaneous and uterine leiomyomata. <span><span class="ref-journal">J Am Acad Dermatol. </span>2005;<span class="ref-vol">52</span>:410–6.</span> [<a href="/pubmed/15761418" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15761418</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.coughlin.1998.254">Coughlin EM, Christensen E, Kunz PL, Krishnamoorthy KS, Walker V, Dennis NR, Chalmers RA, Elpeleg ON, Whelan D, Pollitt RJ, Ramesh V, Mandell R, Shih VE. Molecular analysis and prenatal diagnosis of human fumarase deficiency. <span><span class="ref-journal">Mol Genet Metab. </span>1998;<span class="ref-vol">63</span>:254–62.</span> [<a href="/pubmed/9635293" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9635293</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.farquhar.2002.229">Farquhar CM, Steiner CA. Hysterectomy rates in the United States 1990-1997. <span><span class="ref-journal">Obstet Gynecol. </span>2002;<span class="ref-vol">99</span>:229–34.</span> [<a href="/pubmed/11814502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11814502</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.gardie.2011.226">Gardie B, Remenieras A, Kattygnarath D, Bombled J, Lef&#x000e8;vre S, Perrier-Trudova V, Rustin P, Barrois M, Slama A, Avril MF, Bessis D, Caron O, Caux F, Collignon P, Coupier I, Cremin C, Dollfus H, Dugast C, Escudier B, Faivre L, Field M, Gilbert-Dussardier B, Janin N, Leport Y, Leroux D, Lipsker D, Malthieu F, McGilliwray B, Maugard C, M&#x000e9;jean A, Mortemousque I, Plessis G, Poppe B, Pruvost-Balland C, Rooker S, Roume J, Soufir N, Steinraths M, Tan MH, Th&#x000e9;odore C, Thomas L, Vabres P, Van Glabeke E, Meric JB, Verkarre V, Lenoir G, Joulin V, Deveaux S, Cusin V, Feunteun J, Teh BT, Bressac-de Paillerets B, Richard S., French National Cancer Institute.  "Inherited predisposition to kidney cancer" network. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:226–34.</span> [<a href="/pubmed/21398687" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21398687</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.heinritz.2008.35">Heinritz W, Paasch U, Sticherling M, Wittekind C, Simon JC, Froster UG, Renner R. Evidence for a founder effect of the germline fumarate hydratase gene mutation R58P causing hereditary leiomyomatosis and renal cell cancer (HLRCC). <span><span class="ref-journal">Ann Hum Genet. </span>2008;<span class="ref-vol">72</span>:35–40.</span> [<a href="/pubmed/17908262" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17908262</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.isaacs.2005.143">Isaacs JS, Jung YJ, Mole DR, Lee S, Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, Ratcliffe PJ, Linehan WM, Neckers L. HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. <span><span class="ref-journal">Cancer Cell. </span>2005;<span class="ref-vol">8</span>:143–53.</span> [<a href="/pubmed/16098467" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16098467</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.kiuru.2002.4554">Kiuru M, Lehtonen R, Arola J, Salovaara R, Jarvinen H, Aittomaki K, Sjoberg J, Visakorpi T, Knuutila S, Isola J, Delahunt B, Herva R, Launonen V, Karhu A, Aaltonen LA. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. <span><span class="ref-journal">Cancer Res. </span>2002;<span class="ref-vol">62</span>:4554–7.</span> [<a href="/pubmed/12183404" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12183404</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.knox.1998.25587">Knox C, Sass E, Neupert W, Pines O. Import into mitochondria, folding and retrograde movement of fumarase in yeast. <span><span class="ref-journal">J Biol Chem. </span>1998;<span class="ref-vol">273</span>:25587–93.</span> [<a href="/pubmed/9748223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9748223</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.lamba.2005.332">Lamba M, Verma S, Prokopetz R, Pierscianowski TA, Jabi M, Moyana T. Multiple cutaneous and uterine leiomyomas associated with gastric GIST. <span><span class="ref-journal">J Cutan Med Surg. </span>2005;<span class="ref-vol">9</span>:332–5.</span> [<a href="/pubmed/16699905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16699905</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.launonen.2001.3387">Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA. Inherited susceptibility to uterine leiomyomas and renal cell cancer. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2001;<span class="ref-vol">98</span>:3387–92.</span> [<a href="/pmc/articles/PMC30663/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC30663</span></a>] [<a href="/pubmed/11248088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11248088</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.lehtonen.2006.523">Lehtonen HJ, Kiuru M, Ylisaukko-Oja SK, Salovaara R, Herva R, Koivisto PA, Vierimaa O, Aittomaki K, Pukkala E, Launonen V, Aaltonen LA. Increased risk of cancer in patients with fumarate hydratase germline mutation. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:523–6.</span> [<a href="/pmc/articles/PMC2564537/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564537</span></a>] [<a href="/pubmed/16155190" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16155190</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.lehtonen.2004.17">Lehtonen R, Kiuru M, Vanharanta S, Sjoberg J, Aaltonen LM, Aittomaki K, Arola J, Butzow R, Eng C, Husgafvel-Pursiainen K, Isola J, Jarvinen H, Koivisto P, Mecklin JP, Peltomaki P, Salovaara R, Wasenius VM, Karhu A, Launonen V, Nupponen NN, Aaltonen LA. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. <span><span class="ref-journal">Am J Pathol. </span>2004;<span class="ref-vol">164</span>:17–22.</span> [<a href="/pmc/articles/PMC1602244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1602244</span></a>] [<a href="/pubmed/14695314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14695314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.linehan.2013.3345">Linehan WM, Rouault TA. Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. <span><span class="ref-journal">Clin Cancer Res. </span>2013;<span class="ref-vol">19</span>:3345–52.</span> [<a href="/pmc/articles/PMC4447120/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4447120</span></a>] [<a href="/pubmed/23633457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23633457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.matyakhina.2005.3773">Matyakhina L, Freedman RJ, Bourdeau I, Wei MH, Stergiopoulos SG, Chidakel A, Walther M, Abu-Asab M, Tsokos M, Keil M, Toro J, Linehan WM, Stratakis CA. Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical cushing syndrome: a clinical and molecular genetic investigation. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2005;<span class="ref-vol">90</span>:3773–9.</span> [<a href="/pubmed/15741255" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15741255</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.oflaherty.2010.3844">O'Flaherty L, Adam J, Heather LC, Zhdanov AV, Chung YL, Miranda MX, Croft J, Olpin S, Clarke K, Pugh CW, Griffiths J, Papkovsky D, Ashrafian H, Ratcliffe PJ, Pollard PJ. Dysregulation of hypoxia pathways in fumarate hydratase-deficient cells is independent of defective mitochondrial metabolism. <span><span class="ref-journal">Hum Mol Genet. </span>2010;<span class="ref-vol">19</span>:3844–51.</span> [<a href="/pmc/articles/PMC2935862/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2935862</span></a>] [<a href="/pubmed/20660115" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20660115</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.pithukpakorn.2006.755">Pithukpakorn M, Wei MH, Toure O, Steinbach PJ, Glenn GM, Zbar B, Linehan WM, Toro JR. Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:755–62.</span> [<a href="/pmc/articles/PMC2564577/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564577</span></a>] [<a href="/pubmed/16597677" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16597677</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.reed.1973.409">Reed WB, Walker R, Horowitz R. Cutaneous leiomyomata with uterine leiomyomata. <span><span class="ref-journal">Acta Derm Venereol. </span>1973;<span class="ref-vol">53</span>:409–16.</span> [<a href="/pubmed/4127477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4127477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.ritzmann.2006.84">Ritzmann S, Hanneken S, Neumann NJ, Ruzicka T, Kruse R. Type 2 segmental manifestation of cutaneous leiomyomatosis in four unrelated women with additional uterine leiomyomas (Reed's syndrome). <span><span class="ref-journal">Dermatology. </span>2006;<span class="ref-vol">212</span>:84–7.</span> [<a href="/pubmed/16319483" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16319483</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.smit.2011.49">Smit DL, Mensenkamp AR, Badeloe S, Breuning MH, Simon MEH, van Spaendonck KY, Aalfs CM, Post JG, Shanley S, Krapels IPC, Hoefsloot LH, van Moorselaar RJA, Starink TM, Bayley J-P, Frank J, van Steensel MAM, Menko FH. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. <span><span class="ref-journal">Clin Genet. </span>2011;<span class="ref-vol">79</span>:49–59.</span> [<a href="/pubmed/20618355" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20618355</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.tomlinson.2002.406">Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. <span><span class="ref-journal">Nat Genet. </span>2002;<span class="ref-vol">30</span>:406–10.</span> [<a href="/pubmed/11865300" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11865300</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.toro.2003.95">Toro JR, Nickerson ML, Wei MH, Warren MB, Glenn GM, Turner ML, Stewart L, Duray P, Tourre O, Sharma N, Choyke P, Stratton P, Merino M, Walther MM, Linehan WM, Schmidt LS, Zbar B. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. <span><span class="ref-journal">Am J Hum Genet. </span>2003;<span class="ref-vol">73</span>:95–106.</span> [<a href="/pmc/articles/PMC1180594/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1180594</span></a>] [<a href="/pubmed/12772087" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12772087</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.wei.2006.18">Wei MH, Toure O, Glenn GM, Pithukpakorn M, Neckers L, Stolle C, Choyke P, Grubb R, Middelton L, Turner ML, Walther MM, Merino MJ, Zbar B, Linehan WM, Toro JR. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:18–27.</span> [<a href="/pmc/articles/PMC2564499/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2564499</span></a>] [<a href="/pubmed/15937070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15937070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.ylisaukkooja.2006.283">Ylisaukko-oja SK, Kiuru M, Lehtonen HJ, Lehtonen R, Pukkala E, Arola J, Launonen V, Aaltonen LA. Analysis of fumarate hydratase mutations in a population-based series of early onset uterine leiomyosarcoma patients. <span><span class="ref-journal">Int J Cancer. </span>2006;<span class="ref-vol">119</span>:283–7.</span> [<a href="/pubmed/16477632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16477632</span></a>]</div></li></ul></div><div id="hlrcc.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="hlrcc.REF.menko.2014.637">Menko FH, Maher ER, Schmidt LS, Middelton LA, Aittom&#x000e4;ki K, Tomlinson I, Richard S, Linehan WM. Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. <span><span class="ref-journal">Fam Cancer. </span>2014;<span class="ref-vol">13</span>:637–44.</span> [<a href="/pmc/articles/PMC4574691/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4574691</span></a>] [<a href="/pubmed/25012257" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25012257</span></a>]</div></li></ul></div></div><div id="hlrcc.Chapter_Notes"><h2 id="_hlrcc_Chapter_Notes_">Chapter Notes</h2><div id="hlrcc.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>6 August 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>2 November 2010 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 November 2007 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> available on a clinical basis</div></li><li class="half_rhythm"><div>31 July 2006 (me) Review posted live</div></li><li class="half_rhythm"><div>6 March 2006 (jrt) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1252</span><span class="label">PMID: <a href="/pubmed/20301430" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301430</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/hht/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/accpn/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1252&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1252/?report=reader">PubReader</a></li><li><a href="/books/NBK1252/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1252" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1252" style="display:none" title="Cite this Page"><div class="bk_tt">Pithukpakorn M, Toro JR. Hereditary Leiomyomatosis and Renal Cell Cancer. 2006 Jul 31 [Updated 2015 Aug 6]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1252/pdf/Bookshelf_NBK1252.pdf">PDF version of this page</a> (200K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#hlrcc.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#hlrcc.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#hlrcc.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#hlrcc.Genetically_Related_Allelic_Disord" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#hlrcc.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#hlrcc.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#hlrcc.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#hlrcc.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#hlrcc.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#hlrcc.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#hlrcc.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2271[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FH</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1468370" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1468370" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1468370" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1468370" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23211287" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.</a><span class="source">[Am J Surg Pathol. 2013]</span><div class="brieflinkpop offscreen_noflow">Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sanz-Ortega J, Vocke C, Stratton P, Linehan WM, Merino MJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Surg Pathol. 2013 Jan; 37(1):74-80. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/19075141" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.</a><span class="source">[Arch Dermatol. 2008]</span><div class="brieflinkpop offscreen_noflow">Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stewart L, Glenn GM, Stratton P, Goldstein AM, Merino MJ, Tucker MA, Linehan WM, Toro JR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Arch Dermatol. 2008 Dec; 144(12):1584-92. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31162287" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).</a><span class="source">[Am J Surg Pathol. 2019]</span><div class="brieflinkpop offscreen_noflow">Detailed Morphologic and Immunohistochemical Characterization of Myomectomy and Hysterectomy Specimens From Women With Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome (HLRCC).<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chan E, Rabban JT, Mak J, Zaloudek C, Garg K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Surg Pathol. 2019 Sep; 43(9):1170-1179. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25018647" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary leiomyomatosis and renal cell carcinoma.</a><span class="source">[Int J Nephrol Renovasc Dis. 2014]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary leiomyomatosis and renal cell carcinoma.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schmidt LS, Linehan WM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Int J Nephrol Renovasc Dis. 2014; 7:253-60. Epub 2014 Jun 20.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301744" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301430" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301430" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040db8dd21425a255ff8b5">Hereditary Leiomyomatosis and Renal Cell Cancer - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Hereditary Leiomyomatosis and Renal Cell Cancer - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:32:40-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal102&amp;ncbi_phid=CE8929ACE03F633100000000093E0383&amp;ncbi_session=CE8929ACE040DB81_2366SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1252%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1252&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1252/&amp;ncbi_pagename=Hereditary Leiomyomatosis and Renal Cell Cancer - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8929ACE040DB81_2366SID /projects/books/PBooks@5.22 portal102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>